LEO Pharma A/S

https://www.leo-pharma.com

LEO Pharma is a global pharmaceutical company dedicated to advancing the standard of care for people with skin conditions. Founded in 1908, the company specializes in medical dermatology, focusing on research, development, and marketing of innovative treatments. Its mission is to help people achieve healthy skin by advancing the science of dermatology, improving patient care, and providing access to effective therapies worldwide. LEO Pharma's headquarters are located in Ballerup, near Copenhagen, Denmark.

The company's portfolio includes a wide range of prescription medications and over-the-counter products for various skin conditions, such as psoriasis, eczema (atopic dermatitis), skin infections, and rare skin diseases. Key products include Adtralza®/Adbry® (tralokinumab) for atopic dermatitis, Enstilar® for psoriasis, the Fucidin® range, Protopic® (tacrolimus ointment), and Anzupgo® (delgocitinib) for chronic hand eczema. LEO Pharma is also actively developing new therapies, with a pipeline that includes TMB-001 for Congenital Ichthyosis and a recently acquired gene therapy platform from Replay targeting genetic skin diseases like dystrophic epidermolysis bullosa.

Christophe Bourdon serves as the CEO, having been appointed in April 2022, and is leading the company's strategic transformation to enhance its position in medical dermatology. LEO Pharma has been expanding its pipeline through strategic acquisitions, including key assets from Timber Pharmaceuticals in January 2024 and the gene therapy company Replay in April 2026, to bolster its focus on rare dermatological diseases. The company reported a 10% revenue growth in 2025 and is working towards a potential public listing.

Latest updates

LEO Pharma Acquires Replay for Gene Therapy Push in Rare Skin Diseases

Event summary

  • LEO Pharma has acquired Replay, a gene therapy company, for an undisclosed amount.
  • The acquisition includes an upfront payment of USD 50 million, plus milestone payments and tiered royalties.
  • Replay’s platform utilizes a herpes simplex virus (HSV) delivery vector for topical gene therapy targeting skin cells.
  • The lead drug candidate, targeting dystrophic epidermolysis bullosa (DEB), is currently in preclinical studies.
  • LEO Pharma used its AI-powered scouting platform, Innoviewer™, to identify Replay as a high-potential acquisition.

The big picture

LEO Pharma’s acquisition of Replay underscores the growing interest in gene therapy as a treatment modality for rare diseases, particularly those affecting the skin. The deal, valued at USD 50 million upfront, reflects the increasing premium placed on innovative platforms with the potential to address significant unmet medical needs. This move positions LEO Pharma to compete in a rapidly evolving landscape where targeted therapies are increasingly favored over traditional treatments.

What we're watching

Clinical Progress
The speed of clinical development for Replay’s DEB candidate will be critical, as the condition’s severity and unmet need create high expectations for efficacy.
Platform Scalability
Whether LEO Pharma can successfully expand Replay’s HSV gene therapy platform to address other rare dermatological conditions will determine the long-term value of the acquisition.
Regulatory Pathway
The regulatory pathway for topical gene therapies remains relatively unproven, and LEO Pharma will need to navigate potential hurdles in securing approvals for Replay’s pipeline.

LEO Pharma Gains China Psoriasis Access with Enstilar Approval

Event summary

  • LEO Pharma secured NMPA approval for Enstilar (calcipotriene/betamethasone dipropionate) to treat plaque psoriasis in China.
  • The approval grants access to a new treatment option for an estimated 6.5 million Chinese patients.
  • Enstilar, a foam formulation, demonstrated superiority to Daivobet ointment in a Phase 3 clinical trial.
  • The launch of Enstilar in China is planned for later in 2026.

The big picture

China represents a significant growth opportunity for dermatology companies, driven by a large patient population and increasing healthcare spending. LEO Pharma's success in China will hinge on navigating the evolving regulatory landscape and competing with established players. This approval reinforces LEO Pharma’s strategy of expanding its global footprint, particularly in high-growth markets.

What we're watching

Market Penetration
The speed of Enstilar's adoption in China will depend on physician familiarity and reimbursement policies, potentially impacting LEO Pharma's revenue projections.
Portfolio Expansion
LEO Pharma's stated plans for additional dermatology therapies in China will be crucial to assess the long-term strategic value of this approval.
Competitive Response
Competitors like Daivobet's manufacturer will likely respond with promotional activities or new product development, potentially eroding Enstilar's market share.

LEO Pharma Seeks Pediatric Label Expansion for Hand Eczema Cream

Event summary

  • LEO Pharma submitted a supplemental New Drug Application (sNDA) to the U.S. FDA for ANZUPGO® (delgocitinib) cream to treat chronic hand eczema in pediatric patients aged 12-17.
  • ANZUPGO is currently approved for adults in the U.S. and other regions.
  • The sNDA is based on data from the DELTA TEEN Phase 3 trial, which met its primary and key secondary endpoints.
  • The DELTA TEEN trial compared ANZUPGO cream to a cream vehicle in pediatric patients with moderate to severe chronic hand eczema.
  • The FDA accepted the sNDA on April 15, 2026.

The big picture

LEO Pharma's pursuit of a pediatric label expansion for ANZUPGO reflects a broader trend among pharmaceutical companies to address underserved patient populations and expand the utility of existing drugs. This move positions LEO Pharma to capitalize on a significant unmet medical need, but also exposes them to regulatory scrutiny and potential competition in a niche market. The success of this expansion will be a key indicator of LEO Pharma’s ability to navigate the complexities of pediatric drug development and commercialization.

What we're watching

Regulatory Risk
The FDA's approval timeline and any potential requests for additional data will be critical, as the safety and efficacy in pediatric populations haven't been fully evaluated.
Market Dynamics
The success of ANZUPGO in the pediatric market will depend on physician adoption and patient access, given the lack of existing approved treatments for this age group.
Competitive Landscape
The emergence of alternative therapies or competing JAK inhibitors targeting pediatric hand eczema could erode ANZUPGO's potential market share.

LEO Pharma's Real-World Tralokinumab Data Bolsters AD Treatment Portfolio

Event summary

  • LEO Pharma presented 12-month real-world data from the TRACE study of tralokinumab at the 2026 AAD Annual Meeting.
  • The TRACE study, an international, non-interventional study, included 824 adult patients with atopic dermatitis.
  • Post-hoc analyses showed a marked decrease in H&F involvement (46.3% to 31.6%) and 80.4% of patients with skin of color achieved disease control at 12 months.
  • 91% of patients achieved at least one moderate treatment target after 12 months of tralokinumab.

The big picture

The presentation of this real-world data underscores LEO Pharma's strategy of leveraging post-market studies to expand the utility and acceptance of tralokinumab. This approach is increasingly common in biopharmaceuticals, as payers and clinicians demand evidence beyond clinical trials. The focus on specific subgroups like those with H&F involvement and skin of color highlights a targeted commercialization strategy aimed at addressing unmet needs within the broader atopic dermatitis patient population, a market estimated to be worth billions annually.

What we're watching

Market Adoption
How the positive real-world data will impact tralokinumab's market share and adoption rates, particularly within the competitive landscape of atopic dermatitis treatments, remains to be seen.
Subgroup Expansion
Whether LEO Pharma will continue to pursue and publish data on additional patient subgroups beyond H&F involvement and skin of color to further broaden the drug's appeal and label.
Regulatory Scrutiny
The FDA's assessment of these real-world data and its potential impact on the drug's labeling and marketing authorization will be a key factor in its long-term commercial success.

LEO Pharma's SPEVIGO Data Bolsters Long-Term GPP Treatment Outlook

Event summary

  • LEO Pharma presented long-term data from the EFFISAYIL ON study at the 2026 AAD Annual Meeting.
  • The study showed a reduction in GPP flares from 2.0 per year to 0.13 per year with SPEVIGO treatment.
  • 74.6% of patients on SPEVIGO for three or more years experienced no flares.
  • Intravenous SPEVIGO demonstrated effectiveness in treating flares, with 50% achieving clear pustulation at Week 1.

The big picture

LEO Pharma's SPEVIGO represents a significant advancement in treating GPP, a rare and debilitating condition with limited treatment options. The long-term data reinforces the drug's efficacy but also highlights the complexities of managing a chronic, unpredictable disease. The company's commitment to ongoing data generation and the dual IV/SC approach underscores the need for a comprehensive treatment strategy in this niche market.

What we're watching

Market Adoption
The sustained adoption of SPEVIGO will depend on physician comfort with the IV flare treatment protocol and patient adherence to the subcutaneous maintenance regimen, particularly given the reported adverse event profile.
Competitive Landscape
Emerging therapies targeting the IL-36 pathway could erode SPEVIGO’s market share, necessitating continued innovation and data generation to maintain its clinical advantage.
Regulatory Scrutiny
The reported serious adverse events, particularly GBS, will likely draw increased regulatory scrutiny and require proactive risk mitigation strategies from LEO Pharma.

LEO Pharma Showcases Real-World Data, Signals Pipeline Momentum at AAD 2026

Event summary

  • LEO Pharma will present 17 scientific abstracts at the 2026 AAD Annual Meeting in Denver, Colorado, from March 27-31.
  • Data to be presented includes 12-month real-world evidence for ADBRY® (tralokinumab) in atopic dermatitis patients, outcomes with ANZUPGO® (delgocitinib) cream for chronic hand eczema, and long-term data for SPEVIGO® (spesolimab) in generalized pustular psoriasis.
  • The presentations will focus on real-world effectiveness, long-term outcomes, and patient experience across multiple dermatological conditions.
  • The company is highlighting data from the TRACE, EFFISAYIL, CHECK, and DELTA studies.

The big picture

LEO Pharma's commitment to showcasing real-world data reflects a broader industry trend toward demonstrating the long-term value and impact of pharmaceutical interventions. This strategy is particularly important for specialized therapies targeting niche dermatological conditions, where patient populations are often underserved and treatment outcomes are closely scrutinized. The company's focus on patient experience data also aligns with the growing emphasis on patient-centric healthcare and value-based care models.

What we're watching

Clinical Adoption
The reception of these real-world data presentations will influence physician adoption of ADBRY, ANZUPGO, and SPEVIGO, particularly given the ongoing focus on demonstrating value beyond clinical trials.
Competitive Landscape
How LEO Pharma’s data stack up against emerging therapies in atopic dermatitis, chronic hand eczema, and generalized pustular psoriasis will be crucial in maintaining market share and pricing power.
Regulatory Scrutiny
Continued emphasis on real-world evidence may be driven by increasing regulatory pressure to demonstrate long-term effectiveness and safety profiles of dermatological treatments.

LEO Pharma Bets on DTC Push for Hand Eczema Treatment Amidst Low Awareness

Event summary

  • LEO Pharma launched a direct-to-consumer (DTC) campaign, 'It’s GO time,' for ANZUPGO (delgocitinib) cream on March 5, 2026.
  • ANZUPGO is the first FDA-approved treatment for moderate to severe chronic hand eczema (CHE), approved in July 2025.
  • A 2025 survey revealed that only 30% of U.S. patients with hand eczema are aware of the condition, and nearly 75% find their symptoms frustrating to manage.
  • The campaign targets a patient population of approximately 1 in 10 adults in the U.S. (roughly 33 million people).

The big picture

LEO Pharma's move into DTC marketing represents a shift in strategy for a traditionally physician-focused pharmaceutical company, reflecting a broader trend towards patient empowerment and direct engagement. The low awareness of CHE, despite its prevalence, highlights a significant unmet need and a potential opportunity for targeted marketing. This campaign underscores the growing importance of patient education in driving adoption of specialized therapies, particularly as competition in the dermatology market intensifies.

What we're watching

Campaign Efficacy
The success of the DTC campaign will hinge on its ability to demonstrably increase patient awareness and drive demand for ANZUPGO, which will be reflected in prescription numbers and market share gains.
Competitive Response
Other pharmaceutical companies will likely observe LEO Pharma’s DTC strategy and may consider similar approaches for competing treatments or new entrants in the hand eczema space.
Safety Profile
Continued scrutiny of ANZUPGO’s safety profile, particularly regarding infection risk and skin cancer, will be crucial, as any adverse event reports could significantly impact adoption and marketing efforts.

LEO Pharma's Profitability Surges as Dermatology Portfolio Drives Growth

Event summary

  • LEO Pharma achieved 10% constant exchange rate (CER) revenue growth in 2025, exceeding guidance.
  • Adjusted EBITDA margin more than doubled to 16%, resulting in a DKK 2,107 million profit.
  • Revenue growth was led by North America (+35% CER), with key dermatology brands like Anzupgo® and Spevigo® contributing to a 48% revenue increase.
  • The company returned to positive net profit (DKK 2,489 million) and generated DKK 1,875 million in free cash flow.

The big picture

LEO Pharma's strong performance reflects a successful strategic pivot towards dermatology, capitalizing on the growing demand for specialized treatments. The acquisition of Spevigo® and the U.S. launch of Anzupgo® demonstrate a willingness to expand through both organic innovation and strategic partnerships. The company's return to profitability after a period of losses signals a potential inflection point, but continued execution will be vital to maintaining this momentum in a competitive pharmaceutical landscape.

What we're watching

Growth Sustainability
The continued reliance on North American growth raises questions about geographic diversification and potential saturation risks as the company expands globally.
Margin Pressure
While margins improved significantly, the planned increase in commercial and R&D investments could compress profitability if revenue growth slows.
Pipeline Execution
The success of late-stage trials for Anzupgo® and Spevigo® will be critical to sustaining the current growth trajectory and justifying ongoing investment in innovation.

LEO Pharma Advances Delgocitinib Cream to Phase 3 Trial for Lichen Sclerosus

Event summary

  • LEO Pharma initiated the DELTA CARE 1 phase 3 trial for delgocitinib cream (Anzupgo) in lichen sclerosus (LS).
  • The trial will enroll up to 652 adult patients across 80-90 sites in North America, Europe, and Canada.
  • The primary endpoint is the Investigator’s Global Assessment for LS treatment success (IGA-LS TS) after 12 weeks.
  • Anzupgo is currently approved for chronic hand eczema (CHE) in the U.S., EU, and several other markets.
  • LEO Pharma obtained exclusive rights to delgocitinib for topical dermatological indications in 2014, excluding Japan.

The big picture

LEO Pharma's move to expand Anzupgo’s indication into lichen sclerosus represents a strategic effort to address a significant unmet medical need and diversify its revenue streams beyond chronic hand eczema. The lack of approved treatments for LS creates a substantial market opportunity, but success will depend on demonstrating efficacy and safety in the phase 3 trial. This expansion also underscores the broader trend of pharmaceutical companies seeking to repurpose existing drugs for new indications to accelerate development timelines and reduce costs.

What we're watching

Clinical Efficacy
The trial's success hinges on demonstrating statistically significant efficacy for LS, a condition with limited treatment options, which will be critical for broader adoption.
Regulatory Approval
Approval in the U.S. and Europe will depend on the DELTA CARE 1 trial results and could significantly expand Anzupgo’s market reach, given the disease’s prevalence.
Competitive Landscape
Other pharmaceutical companies may be developing competing therapies for LS, and LEO Pharma’s ability to secure market share will depend on the trial’s outcome and commercialization strategy.

LEO Pharma to Detail Growth Strategy at J.P. Morgan Healthcare Conference

Event summary

  • LEO Pharma CEO Christophe Bourdon will present at the J.P. Morgan Healthcare Conference on January 13, 2026.
  • The conference presentation will focus on LEO Pharma’s innovation strategy, growth momentum, and global ambitions.
  • LEO Pharma serves approximately 100 million patients annually in over 70 countries.
  • The company is co-owned by the LEO Foundation and Nordic Capital, with Nordic Capital joining as a shareholder in 2021.

The big picture

LEO Pharma’s presentation comes amidst a broader trend of consolidation and specialization within the dermatology sector, where companies are increasingly focusing on niche therapeutic areas. The company’s co-ownership structure, with both a foundation and private equity involvement, introduces a unique governance dynamic that could influence long-term strategic decisions. The J.P. Morgan conference provides a key opportunity to assess whether LEO Pharma can maintain its momentum and justify its premium valuation.

What we're watching

Pipeline Risk
The company’s claims of a ‘promising pipeline’ require scrutiny; investors should assess the stage and potential commercial viability of upcoming drug candidates to determine if they can sustain recent growth.
Partner Dependency
LEO Pharma’s reliance on partnerships for innovation could expose it to risks related to partner priorities and potential conflicts of interest, impacting the speed and direction of its development efforts.
Margin Sustainability
While LEO Pharma has demonstrated margin expansion, the sustainability of these gains will depend on its ability to manage pricing pressures and maintain operational efficiency in a competitive market.
CID: 643